Lilly Looks To Spin Off Animal Health, Focus Cash On Pharma Growth
Lilly confirmed that it will separate its Elanco animal health business from the rest of the company via an IPO, allowing Lilly to focus its resources on pharma growth driven by internal and acquired drugs.
You may also be interested in...
Lilly reported strong sales growth for many of its recently launched products, but news of the potentially differentiating REWIND cardiovascular outcomes trial data dominated the pharma’s third quarter earnings call.
AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.
Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development and regulatory strategy for BAN2401 in Alzheimer's. And Gilead investors want reassurance that the company will return to growth soon.